“We continued to make meaningful progress this quarter toward our goal of delivering the first approved treatment for people living with Stargardt disease,” said Dr. Tom Lin, Chairman and CEO of Belite Bio (BLTE). “We are very encouraged by China NMPA’s and UK MHRA’s response to accept New Drug Application for Tinlarebant based on Phase 3 interim results. We remain on track to report final DRAGON topline data in the fourth quarter. In parallel, the completion of our $15 million registered direct offering and $125 million private placement further strengthens our financial position and enables us to continue advancing Tinlarebant toward upcoming regulatory milestones and potential commercial readiness.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio, Inc. ADR (BLTE) Q3 Earnings Cheat Sheet
- Belite Bio announces U.K.’s MHRA accepts CMA application for Tinlarebant
- Belite Bio price target raised to $132 from $80 at Benchmark
- Belite Bio management to meet virtually with Cantor
- Belite Bio files to sell 1.95M American Depositary Shares for holders